Diffuse large B-cell lymphoma-germinal center B cell subtype presenting as cutaneous nodules
Keywords:
Cutaneous, Diffuse large B cell lymphoma, DLBCL, Germinal centre, GCBAbstract
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma worldwide, representing approximately 30-40% of all cases in different geographic regions. We report a case that highlights the atypical presentation of DLBCL-germinal centre B cell subtype as a cutaneous disease. This unique presentation emphasizes the importance of considering DLBCL in the differential diagnosis of patients presenting with infiltrated skin lesions in the absence of classic lymphadenopathy.References
Møller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation- a population-based study of 1575 cases. Br J Haematol. 2004;124:151-9.
Vitolo U, Seymour JF, Martelli M, Illerhaus G, Illidge T, Zucca E, et al. ESMO Guidelines Committee. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v91-v102.
Kilaru S, Panda SS, Mishra S, Mohapatra D, Baisakh M, Kolluri S, Devaraj S, et al. Cutaneous involvement in diffuse large B cell lymphoma at presentation: report of two rare cases and literature review. J Egypt Natl Canc Inst. 2021;33:25.
Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275-82.
Fink-Puches R, Zenahlik P, Bäck B, Smolle J, Kerl H, Cerroni L. Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients. Blood. 2002;99:800-5.
Chatterjee D, Bhattacharjee R. Immunohistochemistry in dermatopathology and its relevance in clinical practice. Indian Dermatol Online J. 2018;9:234-44.
Selva R, Violetti SA, Delfino C, Grandi V, Cicchelli S, Tomasini C, et al. A Literature Revision in Primary Cutaneous B-cell Lymphoma. Indian J Dermatol. 2017;62:146-57.
Senff NJ, Hoefnagel JJ, Jansen PM, Vermeer MH, van Baarlen J, Blokx WA, et al. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol. 2007;25:1581-7.
Zinzani PL, Quaglino P, Pimpinelli N, Berti E, Baliva G, Rupoli S, et al. Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol. 2006;24:1376-82.
Takahashi H, Tomita N, Yokoyama M, Tsunoda S, Yano T, Murayama K, et al. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era. Cancer. 2012;118:4166-72.
Lee WJ, Won KH, Won CH, Chang SE, Choi JH, Moon KC, et al. Secondary Cutaneous Diffuse Large B-cell Lymphoma has a Higher International Prognostic Index Score and Worse Prognosis Than Diffuse Large B-cell Lymphoma, Leg Type. Acta Derm Venereol. 2016;96:245-50.
